ライフサイエンスコーパス: complete remission

1 ponse rate (three partial remissions and one complete remission).

2 myeloid leukemia (AML) patients who entered complete remission.

3 ts who received Hu19-CD828Z T cells obtained complete remission.

4 n the primary intention-to-treat analysis of complete remission.

5 a with more than 90% of the patients showing complete remission.

6 ur DNA was done in 107 patients who achieved complete remission.

7 tial clinical utility for surveillance after complete remission.

8 ponse rate (ORR) was 92%, with 73% achieving complete remission.

9 risk factor were candidates for SCT in first complete remission.

10 ival in patients achieving either partial or complete remission.

11 se, 282 (54%) received a transplant in first complete remission.

12 of HSCT for older patients with AML in first complete remission.

13 confined within the fibrous capsule achieved complete remission.

14 hole-exome sequencing in granulocytes during complete remission.

15 was seen in 10/14 patients (71.4%) achieving complete remission.

16 (3.8%) and all patients ultimately achieved complete remission.

17 adjuvant immunosuppressive therapy to induce complete remission.

18 nts (89%) responded, and 27 (51%) achieved a complete remission.

19 adjuvant immunosuppressive therapy to induce complete remission.

20 nts treated, including in those who achieved complete remission.

21 rate was 51%, with 40% of patients achieving complete remission.

22 Two of the patients had durable complete remissions.

23 lts, and about 50% show partial, rather than complete, remission.

24 ts transplanted, 58 (63%) remained in second complete remission, 13 (14%) died of complications, and

25 (UCT) score, respectively, and patients with complete remission (14.1%) were excluded from analyses.T

26 quency of stable disease >/=6 months/partial/complete remission [22% (high scores) vs. 9% (low scores

27 His cancer remains in complete remission 3 years later without additional trea

28 All three patients with complete remission-3% of the auto-HCT-failed cohort-had

29 d sixty-one of 500 patients (72%) achieved a complete remission, 342/361 completed the consolidation

30 han those without expression (median time to complete remission, 4.0 months vs 5.0 months).

31 ho received their transplantations in second complete remission, 50% for patients in >/= third comple

32 Among the patients who had complete remission, a higher percentage in the inotuzuma

33 bination regimens that increase frequency of complete remissions, accelerate time to remission, and o

34 patients with relapsed NHL or CLL, 2 entered complete remission after 2 and 3 infusions of kappa.CART

35 ts with metastatic melanoma can have durable complete remission after discontinuation of pembrolizuma

36 res of MALT lymphomas, can achieve long-term complete remission after frontline Helicobacter pylori (

37 Those who achieved complete remission after induction therapy were assigned

38 Patients and Methods Patients with AML in complete remission after induction therapy were randomly

39 526 patients achieved complete remission after induction, of whom 463 were ran

40 lapsed/refractory (R/R) lymphomas, including complete remissions among 3 patients with angioimmunobla

41 Long-term complete remission and "cure" of T2DM, however, occur in

42 Of 17 HSCT survivors, 7 are in complete remission and 5 are in good partial remission w

43 ed controls (P < .003), but no mice achieved complete remission and all died within 75 days.

44 III was also associated with a lower rate of complete remission and decreased survival.

45 -79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete rem

46 s achieved persistent antibody depletion and complete remission and never relapsed.

47 esent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inh

48 of adult patients with T-ALL do not achieve complete remission and relapse, our results call for cli

49 mission was lower in the Rtx group, rates of complete remission and the composite renal end point did

50 cluding the proportion of patients achieving complete remission and those with a complete remission w

51 The overall remission rate was 73% with 55% complete remissions and 18% partial remissions.

52 Overall, we observed 9 of 19 complete remissions and 3 of 19 partial remissions.

53 enotype was associated with a higher rate of complete remissions and with a lower frequency of cirrho

54 ete remission, 50% for patients in >/= third complete remission, and 0% for patients not in remission

55 ts, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's

56 showed that 26 of 30 survivors (87%) were in complete remission, and 4 were in remission with ongoing

57 mpairment were intensified enough to achieve complete remission, and addition of BEV increased cell d

58 220 patients achieved second complete remission, and minimal residual disease was eva

59 4%, and 72% in children with IIS resistance, complete remission, and partial remission, respectively;

60 ese drugs have markedly improved the rate of complete remission, and time to progression, progression

61 yeloid leukemia (AML) who are in morphologic complete remission are typically considered separately f

62 esponses in advanced cutaneous melanoma, but complete remissions are frustrated by the development of

63 Eleven of 12 complete remissions are ongoing.

64 However, complete remissions are uncommon and are achieved only a

65 opoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed

66 esity-related comorbidities, and partial and complete remission at 1, 3, and 5 years of follow-up.

67 Two patients were lost to follow-up in complete remission at 12 months.

68 The primary end point was complete remission at 24 weeks.

69 y outcome was the number of patients who had complete remission at any time after anti-CD19 CAR T-cel

70 FR and a 69% reduction in the probability of complete remission at any time, independent of histologi

71 Patients who did not achieve complete remission at the end of the 6-week double-blind

72 The primary end point was complete remission, based on clinical and histologic fac

73 All patients in complete remission by 6 months remained in remission at

74 presence of disease in cases deemed to be in complete remission by conventional pathologic analysis.

75 sive therapy patients, we compared chance of complete remission by logistic regression analysis and u

76 udies, CD38-bispecific PRIT resulted in 100% complete remissions by day 12 in MM and NHL xenograft mo

77 a phototherapeutic-proenzyme approach toward complete-remission cancer therapy.

78 th SR-average disease, the 6-year continuous complete remission (CCR) and OS rates for SC versus IC w

79 busulfan, and melphalan group had stringent complete remission compared with 22 of 174 patients (12.

80 t 6 weeks, 58% of patients given BOT were in complete remission compared with no patients given place

81 karyotypes and led to lower remission rates (complete remission + complete remission with incomplete

82 We assessed a composite primary endpoint of complete remission, complete remission with incomplete p

83 ledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associ

84 Patients in complete remission continued consolidation with dasatini

85 Overall, complete remission (CR [complete remission] + CRi [CR wi

86 months, 67% of patients (all doses) achieved complete remission (CR) + CR with incomplete count recov

87 one (91%) of 45 patients with aGVHD achieved complete remission (CR) after ECP.

88 patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emerg

89 by quantitative polymerase chain reaction at complete remission (CR) and at 3-month time points, and

90 r (CAR) T cell immunotherapy has resulted in complete remission (CR) and durable response in highly r

91 This manuscript evaluates complete remission (CR) and partial remission (PR) of pr

92 during reinduction, 15 of 16 not reaching a complete remission (CR) before transplantation, 9 of 10

93 ute myeloid leukemia (AML) include achieving complete remission (CR) by clinicopathological criteria

94 sing RNA-Seq to compare the RR group and the complete remission (CR) group (a total of 42 adult AML p

95 he combination successfully led to a durable complete remission (CR) in a patient whose disease was r

96 Results Achievement of complete remission (CR) in the absence of MRD negativity

97 ients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arm

98 All patients achieved complete remission (CR) in the bone marrow by flow cytom

99 Achieving BM MRD-negative complete remission (CR) is associated with superior prog

100 ffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) is controversial and plays a lim

101 mes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with est

102 The primary end point was complete remission (CR) on induction.

103 e myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy.

104 nce of relapse (CIR) in patients achieving a complete remission (CR) or CR with incomplete hematologi

105 The primary endpoint was complete remission (CR) or CR with partial haematologica

106 The primary end point was complete remission (CR) or CR with partial hematologic r

107 Complete remission (CR) or sustained partial remission (

108 nt was offered to selected patients in first complete remission (CR) or unconfirmed CR.

109 Complete remission (CR) plus CR with partial hematologic

110 ulting in a significantly higher hematologic complete remission (CR) rate and an equivalent major mol

111 and BIRC3, none of these parameters reduced complete remission (CR) rate and ORR with VenG.

112 ent-related mortality, and effective, with a complete remission (CR) rate of 34%.

113 jective response rate (ORR) was 100% and the complete remission (CR) rate was 62%.

114 With fewer induction deaths, the complete remission (CR) rate was higher in arm A than in

115 Complete remission (CR) rate, including CR with incomple

116 Principal end points were safety and complete remission (CR) rate.

117 osing and had manageable toxicity with a 33% complete remission (CR) rate.

118 Complete remission (CR) rates as high as 90% have been r

119 The complete remission (CR) rates by the Lugano criteria wer

120 mal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/

121 High complete remission (CR) rates often include minimal resi

122 despite achievement of progressively higher complete remission (CR) rates.

123 3 months, participants given FP who were in complete remission (CR) received 880 mcg FP daily, and p

124 Complete remission (CR) was defined as Birmingham Vascul

125 al residual disease (MRD) and achievement of complete remission (CR) with incomplete platelet recover

126 Complete remission (CR) with persistence of mIDH2 and no

127 Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded t

128 Results Patients with MRD-negative complete remission (CR), MRD-negative PR, MRD-positive C

129 ous leukemia (AML) frequently relapses after complete remission (CR), necessitating improved detectio

130 We defined complete remission (CR), partial remission (PR), and rel

131 les taken from patients who went on to enter complete remission (CR), whereas MDR(+) blasts were freq

132 ormed on 702 adults undergoing HSCT in first complete remission (CR).

133 Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count r

134 Rates of response, complete remission (CR/CRi), and undetectable minimal re

135 rapies, and the short-term remission status (complete remission [CR], partial remission [PR], no remi

136 The overall response rate (complete remission [CR]/CR with incomplete count recover

137 splantation (HSCT) is often pursued in first complete remission (CR1).

138 mended monotherapy dose of 40 microg/kg, the complete remission + CRi rate was 28% (5 of 18 patients)

139 Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery o

140 Complete remission, CRp, CRi, and overall survival did n

141 ients obtained remission, which included six complete remissions (CRs) and two partial remissions.

142 se rate was 44% for DLBCL, including 8 (17%) complete remissions (CRs) with a median duration of 16.6

143 Of 15 patients, eight achieved complete remissions (CRs), four achieved partial remissi

144 vemurafenib approached 100%, with 35% to 40% complete remissions (CRs).

145 ipants concluded that the goal of therapy is complete remission, defined as both symptomatic and endo

146 The rate of complete remission did not associate with monogenic clas

147 The pooled complete remission did not significantly differ with ant

148 venous cyclophosphamide group (25.6%) showed complete remission (difference, 20.3 percentage points [

149 1% to 93%), with 67% (52% to 79%), achieving complete remission (five patients [10%] were nonevaluabl

150 Methods Patients with DHL who achieved first complete remission following completion of front-line th

151 medications) in 11%, and "cure" (continuous complete remission for >/=5 years) was achieved in 3%.

152 e primary diagnosis, the patient had been in complete remission for nine years.

153 TD cycles and prevent tumor recurrence after completing remission for certain tumors.

154 Ten (14%) of 69 patients died in complete remission from sepsis (two [3%]), cardiac arres

155 ission (HbA1c <6.5% off medications) in 26%, complete remission (HbA1c <6% off medications) in 11%, a

156 proliferative cells and efficiently induces complete remission; however, many patients relapse and d

157 After >/= 18 months in complete remission, imatinib was tapered and discontinue

158 provement was seen in 88.8% of JMG patients (complete remission in 31.3%) and in 58.3% of CMS patient

159 sulfan, and melphalan who achieved stringent complete remission in accordance with the International

160 ent a generalized framework for clinical and complete remission in asthma, on and off treatment, deve

161 targeting CD19, which offer the prospect of complete remission in patients with chemorefractory or r

162 gager blinatumomab targeting CD19 can induce complete remission in relapsed or refractory B-cell prec

163 A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine grou

164 t inhibition of NPM-ALK induces long-lasting complete remissions in a large subset of heavily pretrea

165 ith metastatic urothelial cancers, including complete remissions in patients with chemotherapy refrac

166 otent antitumor responses, and safely induce complete remissions in patients with leukemia.

167 ukemia (CLL) but as monotherapy produces few complete remissions in previously treated patients.

168 ategy decreasing relapse rates and enhancing complete remissions in this poor prognostic subgroup of

169 The primary end points were complete remission (including complete remission with in

170 Response rate (complete remission + incomplete remission) was the prima

171 Although complete remission is observed in a large proportion of

172 Consequently, IgA-positive patients achieved complete remission less frequently (adjusted hazard rati

173 d or refractory (duration of first composite complete remission <=6 months) FLT3-ITD acute myeloid le

174 ne, as well as treatment outcomes, including complete remission, no response, relapse, early death, a

175 ent antileukemic activity was observed, with complete remission obtained in 73% (11/15) of patients r

176 Complete remission occurred in 6 of 11 patients (54.5%)

177 Complete remission occurred in 6 of 14 patients with dif

178 Complete remissions occurred in 20% of the patients, inc

179 ne patients (52.6%) in the surgery group had complete remission of diabetes and 5 (6.4%) had partial

180 Complete remission of diabetes was maintained in 50.7%,

181 reatment induces granulocytic maturation and complete remission of leukemia.

182 th anti-PD-1, notably, with chemotherapy for complete remission of most lung cancers.

183 g, and high-dose corticosteroids induced the complete remission of neurological symptoms in 4 of 5 pa

184 and selenium supplementation, resulted in a complete remission of ophthalmic symptoms.

185 id PD, treatment with mGluR2 PAM resulted in complete remission of panic symptoms.

186 A higher rate of complete remission of T2DM was observed in patients with

187 ); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a comp

188 come was the proportion of participants with complete remission of type 2 diabetes (HbA(1c) of <=6.0%

189 Complete remissions of a variety of B-cell malignancies

190 DC/CoAT induced durable and complete remissions of large subcutaneous tumors without

191 Complete remission off anti-seizure medications is possi

192 Rituximab induces complete remission off therapy in 90% of patients, despi

193 Among 12 patients who achieved complete remission on earlier trials (ALL 97/99 and UKAL

194 responses at 12 weeks yielded two continuous complete remissions, one partial response (PR) using REC

195 6 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed aft

196 at the recommended phase 2 dose who achieved complete remission or complete remission with incomplete

197 mg/day, 80 mg/day, and 160 mg/day) achieved complete remission or complete remission with incomplete

198 combined treatment, 88% of the patients had complete remission or complete remission with incomplete

199 ssociated with a transplant performed not in complete remission or from a cord-blood unit, a relapse

200 Patients in complete remission or partial remission received six rei

201 Complete remission or partial remission was achieved in

202 n applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse mo

203 ssion duration >=24 months and attainment of complete remission or undetectable measurable residual d

204 e in the proportion of patients who achieved complete remission or who had cytokine release syndrome

205 omplete remission, partial remission, marrow complete remission, or haematological improvement were i

206 eiving peripheral blood stem cells, being in complete remission, or receiving the same associated imm

207 ciated with therapy intensity, likelihood of complete remission, or survival (high income: adjusted H

208 and for the 34 patients (19.3%) who attained complete remission, overall survival was 19.7 months.

209 ume decreased significantly in patients with complete remission (P = 0.03).

210 346 patients in paediatric studies achieved complete remission, p=0.24.

211 Complete remission, partial remission, marrow complete r

212 nders and partial remission patients than in complete remission patients.

213 Once in complete remission, patients received 4 cycles of ATRA p

214 FCR improved complete remission, PFS and overall survival vs the comp

215 8 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible

216 CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 9

217 In patients who experienced complete remissions, PRs, or stable disease, the persist

218 The overall response rate was 72% (complete remission [R]/major/partial R: 0%/47%/25%) and

219 and higher stable disease >=6 months/partial/complete remission rate (52.1% versus 30.4% P < 0.001) (

220 There was no overall difference in complete remission rate (73% vs 75%; odds ratio, 1.07 [0

221 After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD

222 pliceosome mutations associated with a lower complete remission rate (P = 0.03).

223 The complete remission rate /complete remission with incompl

224 itaxel significantly improves the pathologic complete remission rate compared with weekly solvent-bas

225 UP98/NSD1 (82% of NUP98/NSD1 patients) had a complete remission rate of 27% vs 69% in FLT3/ITD withou

226 ts treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared

227 RR (95% CI) was 73% (54% to 88%), with a 37% complete remission rate per investigator, and ORR of 70%

228 3 patients; 95% CI, 56.3% to 92.5%), and the complete remission rate was 60.9% (14/23 patients; 95% C

229 The complete remission rate was 70%.

230 The complete remission rate was 96% (52 of 54 in high-risk a

231 Complete remission rate was 96% and 65% of patients achi

232 were maximum-tolerated dosage (phase I) and complete remission rate within the first two cycles (pha

233 endpoint of the first randomisation was the complete remission rate, analysed by modified intention

234 h worse clinical outcomes, including a lower complete remission rate, more frequent reinduction, and

235 erse cytogenetics were associated with lower complete remission rates (87.7%, 86.0%, and 66.3% for no

236 Complete remission rates (89%) did not differ but were a

237 toxic exposure was associated with decreased complete remission rates and inferior survival (3-year a

238 In spite of high complete remission rates in Acute Myeloid Leukemia (AML)

239 uced an almost 100% response rate, including complete remission rates of 35% to 42%, without myelotox

240 effect on minimal residual disease-negative complete remission rates or subsequent persistence of fu

241 n strategies continue to focus on increasing complete remission rates that allow more transplant-elig

242 EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and ove

243 Patients in complete remission received maintenance with ponatinib 4

244 psed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon.

245 All patients who did not achieve complete remission remained PET-positive (P = 0.02).

246 c cell transplantation at the time of second complete remission remains the only reliable option with

247 achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with inc

248 r in samples from patients with pathological complete remission than in samples from patients with di

249 ry, and the patient's MM entered a stringent complete remission that lasted for 17 weeks before relap

250 L with all-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL

251 ients with myeloid malignancy in morphologic complete remission to myeloablative conditioning (MAC) o

252 Complete remission (tumor-free fraction, 100%) was found

253 on chemotherapy, 49 (70%) remained in second complete remission, two (3%) died of complications, and

254 nosis and had achieved complete remission or complete remission unconfirmed after first-line rituxima

255 udy start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane(R) only group

256 dy start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group

257 of patients with aggressive NHL who achieved complete remission was 20.0 months (median follow-up, 26

258 The pooled complete remission was 80% (95% CI 75.5-84.8) and hetero

259 However, complete remission was achieved first at activity levels

260 Complete remission was achieved in 40% (6/15 of evaluabl

261 Complete remission was defined as clinical remission plu

262 The rate of complete remission was higher with inotuzumab ozogamicin

263 Complete remission was induced after two courses of ther

264 tly slower in the aFP + anti-PD-1 groups and complete remission was observed for tumors on both aFP-t

265 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%.

266 Complete remission was observed in one patient with TC,

267 groups (aFP and aFP + anti-PD-1 groups) and complete remission was observed in the aFP-treated group

268 The rate of complete remission was significantly higher in the inotu

269 ripheral blood lymphocyte counts and time to complete remission were shorter, and residual disease le

270 All 25 complete remissions were preceded by complete anti-PLA2R

271 ovillous transformation were associated with complete remission, whereas endothelial cell and glomeru

272 s, this in contrast to several patients with complete remission who also experienced late relapses 4

273 The patient had complete remission with antibiotic and anti-inflammatory

274 ions, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R.

275 tients with relapsed/refractory ALL achieved complete remission with full (CR) or partial (CRh) hemat

276 the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% v

277 y (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hem

278 io for an event of relapse after achieving a complete remission with full, partial, or incomplete hem

279 One complete remission with incomplete count recovery was ob

280 8% of the patients had complete remission or complete remission with incomplete count recovery, and 6

281 with incomplete platelet recovery, 46 (18%) complete remission with incomplete haematological recove

282 se 2 dose who achieved complete remission or complete remission with incomplete haematological recove

283 with incomplete platelet recovery (CRp), and complete remission with incomplete haematological recove

284 nd points were complete remission (including complete remission with incomplete hematologic recovery)

285 chieving complete remission and those with a complete remission with incomplete neutrophil or platele

286 complete remission and five (13%) achieving complete remission with incomplete neutrophil or platele

287 site primary endpoint of complete remission, complete remission with incomplete platelet recovery (CR

288 The complete remission rate /complete remission with incomplete platelet recovery rat

289 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46

290 d 160 mg/day) achieved complete remission or complete remission with incomplete recovery of platelets

291 lower remission rates (complete remission + complete remission with incomplete recovery), inferior e

292 acute myeloid leukemia (AML) do not achieve complete remission with intensive induction therapy and

293 The primary end point was the rate of complete remission with undetectable minimal residual di

294 eatment, the proportions of patients who had complete remission (with or without normal blood count r

295 % (95% CI 10-48) in six patients with marrow complete remission, with an additional 12 patients (52%,

296 to therapeutic outcome (defined as achieving complete remission within 63 days) and duration of leuke

297 ed that nearly all patients (98.4%) achieved complete remission within the first three steps.

298 osage, 27 (39%; 95% CI, 27% to 51%) achieved complete remission within the first two cycles, 14 (52%)

299 he initial diagnosis the patient is still in complete remission without any treatment.

300 Complete remission without minimal residual disease seem